BiotechTube

Inclisiran + Evolocumab

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Atherosclerotic Cardiovascular Disease

Conditions

Atherosclerotic Cardiovascular Disease, Symptomatic Atherosclerosis, Type2 Diabetes, Familial Hypercholesterolemia

Trial Timeline

Apr 27, 2017 → Dec 17, 2021

NCT ID
NCT03060577

About Inclisiran + Evolocumab

Inclisiran + Evolocumab is a phase 2 stage product being developed by Novartis for Atherosclerotic Cardiovascular Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT03060577. Target conditions include Atherosclerotic Cardiovascular Disease, Symptomatic Atherosclerosis, Type2 Diabetes.

What happened to similar drugs?

8 of 20 similar drugs in Atherosclerotic Cardiovascular Disease were approved

Approved (8) Terminated (0) Active (12)
✅Rosuvamibe + MonorovaYuhanApproved
✅Rosuvamibe + MonorovaYuhanApproved
✅Clopidogrel + TicagrelorAstraZenecaApproved
✅atorvastatin + inclisiranNovartisApproved
✅InclisiranNovartisApproved
✅EvolocumabAmgenApproved
✅Placebo + EvolocumabAmgenApproved

Hype Score Breakdown

Clinical
12
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT03060577Phase 2Completed

Competing Products

20 competing products in Atherosclerotic Cardiovascular Disease

See all competitors
ProductCompanyStageHype Score
Rosuvamibe + MonorovaYuhanApproved
39
Rosuvamibe + MonorovaYuhanApproved
43
Lepodisiran Sodium + PlaceboEli LillyPhase 3
44
Retatrutide + PlaceboEli LillyPhase 3
44
Placebo + AZD0780AstraZenecaPhase 2
35
Clopidogrel + TicagrelorAstraZenecaApproved
43
Epanova® (omega-3 carboxylic acids) + corn oil controlAstraZenecaPhase 3
40
atorvastatin + placeboMerckPhase 1
29
Anacetrapib + Placebo anacetrapibMerckPhase 3
44
Atorvastatin + Simvastatin + Rozuvastatin + Ezetimibe + Niacin + Ciprofibrate + Fenofibrate + Bezafibrate + Evolocumab + Alirocumab + InclisiranNovartisPre-clinical
33
Ranolazine 500 mgNovartisPhase 2
27
Inclisiran + Background lipid lowering therapyNovartisPhase 3
40
Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL + Placebo in 1.5mlNovartisPhase 3
44
atorvastatin + inclisiranNovartisApproved
47
TQJ230 + PlaceboNovartisPhase 3
44
Inclisiran + PlaceboNovartisPhase 3
44
PelacarsenNovartisPre-clinical
30
InclisiranNovartisPhase 3
40
InclisiranNovartisApproved
47
Pelacarsen (TQJ230)NovartisPhase 3
47